knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 00:48:07 - browse：5414

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Gene therapy for Afghan refugees’ infant will be fully covered

WSS

Problems with a popular proposal to regulate AI in health care

The Biogen Aduhelm mess could happen again

Study on Amgen’s bispecific immunotherapy produces positive data

Why a market frenzy over new weight loss drugs defies logic

Is there really a nursing shortage in the U.S.?

Padmanee Sharma of MD Anderson at center of lawsuit over credit

focus

knowledge

A Worst CEO gets some much-needed help

knowledge

Psychedelics group wrestles with new pharma identity

Top private equity targets in 2023: cardiology, clinical trials, lasers

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: Live from the 2023 STAT Summit

Apple is now the first public company to be valued at $3 trillion

STAT Summit: The economic case for universal basic health care

The cancer drug shortage isn’t new — and neither are the solutions

Adopting new red light myopia treatments may be short

Walensky prepares to leave CDC — and Congress — behind

Padmanee Sharma of MD Anderson at center of lawsuit over credit

entertainment

J&J lung cancer data amount to new salvo against AstraZeneca

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

STAT Summit: The economic case for universal basic health care

Problems with a popular proposal to regulate AI in health care

FDA clears Verve to begin U.S. study of gene

Questions loom on AstraZeneca cancer drug as safety concerns ebb

knowledge

hotspot

leisure time

focus